Santosh Vetticaden
Fondateur chez Visgenx, Inc.
Profil
Santosh J.
Vetticaden is the founder of Visgenx, Inc. He is currently the Vice Chairman at Public Health Foundation Enterprises.
Previously, he held senior positions at various pharmaceutical companies including Cubist Pharmaceuticals LLC, Scios, Inc., and Aventis Pharmaceuticals, Inc. He also served as the Chief Medical Officer & Senior Vice President at Maxygen, Inc. and Mast Therapeutics, Inc. Additionally, he was the Chief Executive & Medical Officer at INSYS Therapeutics, Inc. Dr. Vetticaden received his doctorate degrees from the University of Maryland and Virginia Commonwealth University, and his undergraduate degree from Banaras Hindu University.
Postes actifs de Santosh Vetticaden
| Sociétés | Poste | Début |
|---|---|---|
Visgenx, Inc.
 Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | Fondateur | - |
| Public Health Foundation Enterprises | Directeur/Membre du Conseil | - |
Anciens postes connus de Santosh Vetticaden
| Sociétés | Poste | Fin |
|---|---|---|
Assertio Therapeutics, Inc.
 Assertio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL. | Directeur Technique/Scientifique/R&D | 30/04/2018 |
| INSYS THERAPEUTICS, INC. | Directeur Général | 17/04/2017 |
Mast Therapeutics, Inc.
 Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | Directeur Technique/Scientifique/R&D | 01/09/2014 |
| CUBIST PHARMACEUTICALS INC | Directeur Technique/Scientifique/R&D | 19/01/2012 |
Maxygen, Inc.
 Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Directeur Technique/Scientifique/R&D | 15/08/2008 |
Formation de Santosh Vetticaden
| Banaras Hindu University | Undergraduate Degree |
| University of Maryland | Doctorate Degree |
| Virginia Commonwealth University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Maxygen, Inc.
Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA. | Commercial Services |
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Cubist Pharmaceuticals LLC operates as a biopharmaceutical company. It focuses on the research, development and commercialization of pharmaceutical products. The company was founded in 1992 and is headquartered in Lexington, MA. | Health Technology |
Scios, Inc.
 Scios, Inc. Pharmaceuticals: MajorHealth Technology Scios Inc. developed, manufactured, and commercialized pharmaceuticals for conditions such as cardiovascular and inflammatory diseases. The company was founded in 1981 and was headquartered in Sunnyvale, CA. | Health Technology |
Aventis Pharmaceuticals, Inc.
 Aventis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aventis Pharmaceuticals, Inc. develops, manufactures and markets pharmaceutical products. The company was founded in 1950 and is headquartered in Bridgewater, NJ. | Health Technology |
Wyeth Corp.
 Wyeth Corp. Pharmaceuticals: MajorHealth Technology Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ. | Health Technology |
Mast Therapeutics, Inc.
Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA. | Health Technology |
INSYS Therapeutics, Inc.
 INSYS Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology INSYS Therapeutics, Inc. operates as a pharmaceutical company, which develops and commercializes supportive care products. It focuses on utilizing commercial pharmaceutical products that include Subsys, a proprietary sublingual fentanyl spray for BTCP in opioid-tolerant adult patients; and Syndros, a proprietary orally administered liquid formulation of dronabinol for the treatment of CINV and anorexia associated with weight loss in patients with AIDS. The company was founded by John N. Kapoor on June 15, 1990 and is headquartered in Chandler, AZ. | Health Technology |
Assertio Therapeutics, Inc.
Assertio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Assertio Therapeutics, Inc. engages in the manufacture and distribution of pharmaceutical products to treat pain and other central nervous system conditions. Its brands include Gralise, Zipsor, Lazanda, Cambia, NUCYNTA ER and NUCYNTA. The firm focuses on neurology, orphan and specialty medicines. The company was founded by John W. Shell on August 7, 1995 and is headquartered in Lake Forest, IL. | Health Technology |
Visgenx, Inc.
Visgenx, Inc. BiotechnologyHealth Technology Visgenx, Inc. engages in the development of therapeutics to protect against the loss of sight from retinal disorders. Its product pipeline includes Intravitreal Decitabine and gene therapy. The company was founded by Santosh J. Vetticaden and Robert Martin Emanuele and is headquartered in San Diego, CA. | Health Technology |
| Public Health Foundation Enterprises |